[Hydroxyurea treatment in patients affected with sickle cell anemia: efficacy and safety]. / Traitement des patients drépanocytaires par hydroxyurée: efficacité et tolérance.
Transfus Clin Biol
; 15(1-2): 34-8, 2008.
Article
em Fr
| MEDLINE
| ID: mdl-18499496
ABSTRACT
Hydroxyurea is the unique drug having demonstrated an efficacy in preventing recurrences of painful crises, acute chest syndromes and in reducing transfusional needs in patients severely affected with sickle cell disease. However, there is a wide variation in the clinical response to hydroxyurea in sickle cell patients, with children generally experiencing greater benefits than adults. Short- and middle-term tolerances are good. Our uncertainties about long-term tolerance are mainly that we do not know the consequences of the drug on ulterior fertility in boys treated early and for long periods. Hydroxyurea has just been licensed for sickle cell adults and children in Europe. Its prescription for the moment must be restricted to severely affected patients, enrolled in long-term follow-up protocols.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hidroxiureia
/
Anemia Falciforme
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Humans
Idioma:
Fr
Revista:
Transfus Clin Biol
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
França